SELLEST OSAST
Featuring a slide presentation and related discussion from Dr Saad Zafar Usmani, including the following topics:
- Evolution of therapeutic decision-making for patients with newly diagnosed multiple myeloma (MM) (0:00)
- Quadruplet therapy for transplant-eligible patients with newly diagnosed MM (6:26)
- Daratumumab with lenalidomide as maintenance therapy after transplant in newly diagnosed MM (16:16)
- Therapeutic options for transplant-ineligible patients with MM (19:51)
Inglise
Ameerika Ühendriigid
TRANSKRIBEERI 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
OTSI VARASEMAID OSASID
Otsi kanali Research To Practice | Oncology Videos viimaseid osasid.
MUUD EPISOOD SELLES PODCASTIS
Featuring perspectives from Dr Nicoletta Colombo, Dr Gottfried E Konecny, Dr Alexander B Olawaiye and Dr Shannon N Westin, moderated by Dr Westin, including the following topics:
Case: A woman in her mid 50s with BRCA1-mutated recurrent ovarian cancer receives mirvetuximab soravtansine — Ursula …
Featuring perspectives from Dr Catherine C Coombs, including the following topics:
Phase III BRUIN CLL-322 trial of fixed-duration pirtobrutinib in combination with venetoclax and rituximab for previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) (0:00)
Role…
Featuring perspectives from Dr Spencer Bachow, Dr Bhavana (Tina) Bhatnagar, Dr Jennifer Crombie, Dr Manali Kamdar and Ms Alexandra Lynch, co-moderated by Dr Bachow and Dr Bhatnagar, including the following topics:
Introduction and Overview of Bispecific Antibodies in the Clinic (0:00)
Current a…
Featuring a slide presentation from Dr Julia Rotow, including the following topics:
Rationale and potential clinical role of PD-1/PD-L1 x vascular endothelial growth factor (VEGF) bispecific antibodies in the treatment of non-small cell lung cancer (NSCLC) (0:00)
Key findings from the Phase III…
Featuring perspectives from Dr Catherine C Coombs, including the following topics:
Early versus delayed addition of obinutuzumab to acalabrutinib and venetoclax in treatment-naïve chronic lymphocytic leukemia (CLL) (0:00)
Feasibility of discontinuation of Bruton tyrosine kinase (BTK) inhibitor …
Vastutamatussäte: Sellele lehele manustatud taskuhäälingusaade ja kunstiteosed pärinevad Dr Neil Love-lt, mis on selle omaniku omand ja ei ole seotud ettevõttega Listen Notes, Inc.
MUUDA
Aitäh, et aitad hoida podcastide andmebaasi ajakohasena.
